Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Owen

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Blood Advances|June 24, 2020
TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiationJennifer Shrimpton, Matthew A Care, Jonathan Carmichael, et al.
American Journal of Respiratory and Critical Care Medicine|May 14, 2010
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumJames F Donohue, Charles Fogarty, Jan Lötvall, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 28, 2002
Muscarinic receptor antagonist-induced lenticular opacity in ratsGeneviève Durand, Marie-Françoise Hubert, Hiroshi Kuno, et al.
Hemasphere|July 31, 2023
Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for RomiplostimAdam Al-Hakim, Alyssa Cull, Joanna Topping, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
Leukemia & Lymphoma|December 29, 2012
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myelomaAnnamaria Brioli, Martin F Kaiser, Charlotte Pawlyn, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Life Science Alliance|July 28, 2025
Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiationPanagiota Vardaka, Ben Kemp, Sophie Stephenson, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Blood Advances|June 24, 2020
TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiationJennifer Shrimpton, Matthew A Care, Jonathan Carmichael, et al.
American Journal of Respiratory and Critical Care Medicine|May 14, 2010
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumJames F Donohue, Charles Fogarty, Jan Lötvall, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 28, 2002
Muscarinic receptor antagonist-induced lenticular opacity in ratsGeneviève Durand, Marie-Françoise Hubert, Hiroshi Kuno, et al.
Hemasphere|July 31, 2023
Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for RomiplostimAdam Al-Hakim, Alyssa Cull, Joanna Topping, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
Leukemia & Lymphoma|December 29, 2012
Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myelomaAnnamaria Brioli, Martin F Kaiser, Charlotte Pawlyn, et al.
BMC Hematology|May 19, 2016
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myelomaSarah Brown, Samantha Hinsley, Mónica Ballesteros, et al.
Haematologica|December 10, 2020
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trialCharlotte Pawlyn, David Cairns, Tom Menzies, et al.
British Journal of Haematology|June 12, 2020
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myelomaCeri Bygrave, Charlotte Pawlyn, Faith Davies, et al.
Life Science Alliance|July 28, 2025
Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiationPanagiota Vardaka, Ben Kemp, Sophie Stephenson, et al.
Pageof 8